Sickle cell anemia (SCA) is an inherited red blood disorder. The kidneys are among the most commonly affected organ systems in SCA. The Food and Drug Administration (FDA) has approved empagliflozin as a treatment to reduce the decline of kidney function in those with kidney disease. The proposed research study aims to determine whether empagliflozin can prevent the progression of kidney dysfunction in patients with sickle cell anemia (SCA) who are at high risk of developing advanced chronic kidney disease (CKD).
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Efficacy of empagliflozin - urine biomarker: Adenosine
Timeframe: From enrollment to the end of treatment at 48 weeks
Efficacy of empagliflozin - urine biomarker: Nephrin
Timeframe: From enrollment to the end of treatment at 48 weeks
Efficacy of empagliflozin - urine biomarker: Kidney injury molecule-1
Timeframe: From enrollment to the end of treatment at 48 weeks
Efficacy of empagliflozin R2* Cortical Oxygenation on kidney fMRI
Timeframe: From enrollment to the end of treatment at 48 weeks